Immunic, Inc. | Finanzwire

Basculer en Français

8298	Companies
114933	Keywords
55342	Articles
62466	Press releases

Home
Companies
Immunic, Inc.

BRIEF

published on 03/07/2024 at 12:35, 8 months 14 days ago

Immunic, Inc. Announces Participation in Upcoming Investor and Scientific Conferences

Investor Conference Immunic, Inc. Autoimmune Diseases Scientific Conference Chronic Inflammatory
PRESS RELEASE

published on 03/07/2024 at 12:30, 8 months 14 days ago

Immunic to Participate in Investor and Scientific Conferences in March
Immunic, Inc. (Nasdaq: IMUX) announces participation in investor and scientific conferences in March, presenting abstracts and posters showcasing their clinical pipeline of therapies for inflammatory and autoimmune diseases

Investor Conference Biotechnology Clinical Pipeline Scientific Conference Immunic Inc
PRESS RELEASE

published on 02/29/2024 at 12:30, 8 months 21 days ago

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
Immunic presents data from phase 2 CALLIPER and CALVID-1 trials of vidofludimus calcium at ACTRIMS Forum 2024. Positive results on serum neurofilament levels and EBV reactivation

Multiple Sclerosis Immunic Vidofludimus Calcium Phase 2 Trials ACTRIMS Forum
BRIEF

published on 02/29/2024 at 12:30, 8 months 21 days ago

Immunic, Inc. Presents Phase 2 Trial Data on Vidofludimus Calcium at ACTRIMS 2024 Forum

ACTRIMS Forum 2024 Multiple Sclerosis Immunic Vidofludimus Calcium Phase 2 Trials
PRESS RELEASE

published on 02/22/2024 at 12:30, 8 months 28 days ago

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
Immunic, Inc. reports year end 2023 financial results and provides corporate update, including strengthened balance sheet and upcoming clinical milestones. Webcast scheduled for February 22, 2024

Financial Results Webcast Corporate Update Immunic Inc. Clinical Milestones
BRIEF

published on 02/22/2024 at 12:30, 8 months 28 days ago

Immunic, Inc. announces its 2023 annual financial results and corporate update

Immunic, Inc. Annual Financial Results Inflammatory Diseases Multiple Sclerosis Oral Therapies
PRESS RELEASE

published on 02/15/2024 at 12:30, 9 months 6 days ago

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
Immunic, Inc. to announce financial results and corporate update for the year ended December 31, 2023. Webcast on February 22, 2024, at 8:00 am ET

Financial Results Webcast Corporate Update Immunic Inc. Clinical Pipeline
PRESS RELEASE

published on 02/01/2024 at 12:30, 9 months 20 days ago

Immunic to Participate in Investor and Scientific Conferences in February
Immunic, Inc. (Nasdaq: IMUX) to participate in BioCapital Europe 2024 and ACTRIMS Forum 2024 in February and March, presenting clinical pipeline therapies and poster presentations

Immunic, Inc. BioCapital Europe 2024 ACTRIMS Forum 2024 Clinical Pipeline Therapies Poster Presentations
PRESS RELEASE

published on 11/02/2023 at 11:30, 1 year ago

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
PRESS RELEASE

published on 10/26/2023 at 12:30, 1 year ago

Immunic to Participate in Scientific and Industry Conferences in November

Accesswire

Published on 11/21/2024 at 14:00, 18 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 18 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 18 minutes ago

Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:00, 18 minutes ago

GameSquare's Stream Hatchet Publishes Q3 Report
Published on 11/21/2024 at 13:30, 48 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:00, 18 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:15, 1 hour 3 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 43 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 2 hours 3 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 2 hours 11 minutes ago

IVU AG publishes Quarterly Report Q3-2024

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 20 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 58 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 33 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 33 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE